Document:

Exhibit 4.1

  

 

NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE
OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE COMPANY.

 

SKYLINE MEDICAL INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

	 	 	 
	Warrant No. 2017-[    ]	 	Original Issue Date: [               ], 2017

 

Skyline Medical Inc., a Delaware corporation (the “Company”),
hereby certifies that, for value received, [            ] or its permitted
registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of [            ]
shares of common stock, $0.01 par value (the “Common Stock”), of the Company (each such share, a “Warrant
Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $______
(as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), at any time and from
time to time from on or after the date hereof (the “Trigger Date”) and through and including 4:30 P.M., prevailing
Minneapolis time, on [ ], 20___ (the “Expiration Date”), and subject to the following terms and conditions:

 

This Warrant (this “Warrant”)
is one of a series of similar warrants issued pursuant to that certain Securities Purchase Agreement, dated [__________________],
2017, by and among the Company and the Purchasers identified therein (the “Purchase Agreement”). All such warrants
are referred to herein, collectively, as the “Warrants.”

 

1.        Definitions.
In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Purchase Agreement.

  

2.        Registration of
Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

      

     

    

 

3.        Registration of
Transfers. Subject to the restrictions on transfer set forth in Section 4.1 of the Purchase Agreement and compliance with all
applicable securities laws, the Company shall register the transfer of all or any portion of this Warrant in the Warrant Register,
upon (i) surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed,
to the Company’s transfer agent or to the Company at its address specified herein and (ii) if the Registration Statement
is not effective, (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company
to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee of a
written statement to the Company certifying that the transferee is an “accredited investor” as defined in Rule 501(a)
under the Securities Act and making the representations and certifications set forth in Section 3.2(b), (c) and (d) of the Purchase
Agreement, to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant
to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing
the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion
of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the
transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a Holder of a Warrant.

 

4.        Exercise and Duration of Warrants.

 

(a)        Subject
to Section 11 hereof, all or any part of this Warrant shall be exercisable by the registered Holder at any time and from time to
time on or after the Trigger Date and through and including 4:30 P.M. prevailing Minneapolis time on the Expiration Date. At 4:30
P.M., prevailing Minneapolis time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and
become void and of no value and this Warrant shall be terminated and no longer outstanding;

 

(b)       The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto
(the “Exercise Notice”), appropriately completed and duly signed, (ii) payment of the Exercise Price in immediately
available funds for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless
exercise” if so indicated in the Exercise Notice and if a “cashless exercise” may occur at such time pursuant
to Section 10 below), and the date such items are delivered to the Company (as determined in accordance with the notice provisions
hereof) is an “Exercise Date.” The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable
Exercise Price as provided above shall constitute the Holder’s certification to the Company that its representations contained
in Section 3.2(b), (c) and (d) of the Purchase Agreement are true and correct as of the Exercise Date as if remade in their entirety
(or, in the case of any transferee Holder that is not a party to the Purchase Agreement, such transferee Holder’s certification
to the Company that such representations are true and correct as to such assignee Holder as of the Exercise Date). The Holder shall
not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise
Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to
purchase the remaining number of Warrant Shares.

 

     2 

4817-3601-5703, v. 1

     

    

 

5.        Delivery of Warrant
Shares. Upon exercise of this Warrant, the Company shall promptly (but in no event later than three Trading Days after the
Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name
or names as the Holder may designate (provided that, if the Registration Statement is not effective and the Holder directs the
Company to deliver a certificate for the Warrant Shares in a name other than that of the Holder or an Affiliate of the Holder,
it shall deliver to the Company on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect
that the issuance of such Warrant Shares in such other name may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws), a certificate for the Warrant Shares
issuable upon such exercise, free of restrictive legends, unless a registration statement covering the resale of the Warrant Shares
and naming the Holder as a selling stockholder thereunder is not then effective or the Warrant Shares are not freely transferable
pursuant to Rule 144 under the Securities Act pursuant to transactions in which paragraph (c)(1) of such rule do not apply. The
Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder
of record of such Warrant Shares as of the Exercise Date. If the Warrant Shares are to be issued free of all restrictive legends,
the Company shall, upon the written request of the Holder, use its best efforts to deliver, or cause to be delivered, Warrant Shares
hereunder electronically through The Depository Trust Company or another established clearing corporation performing similar functions,
if available; provided, that, the Company may, but will not be required to, change its transfer agent if its current transfer agent
cannot deliver Warrant Shares electronically through such a clearing corporation.

 

6.        Charges, Taxes and
Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance
of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company
shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates
for Warrant Shares or Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible
for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon
exercise hereof.

 

7.        Replacement of Warrant.
If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution
for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable
indemnity (which shall not include a surety bond), if requested. Applicants for a New Warrant under such circumstances shall also
comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may
prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated
Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

8.        Reservation of Warrant
Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but
unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of
this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this
entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into
account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable
shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly
authorized, issued and fully paid and nonassessable. The Company will take all such action as may be necessary to assure that such
shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of any securities exchange or automated quotation system upon which the Common Shares may be listed.

 

     3 

4817-3601-5703, v. 1

     

    

 

9.        Certain Adjustments.
The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time
as set forth in this Section 9.

 

(a)       
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on
its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii)
subdivides its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common
Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator
of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.

 

(b)       Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the
Company with or into another Person, in which the shareholders of the Company as of immediately prior to the transaction own less
than a majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all or substantially all
of its assets or a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions,
(iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which all or substantially
all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property and
would result in the shareholders of the Company immediately prior to such tender offer or exchange offer owning less than a majority
of the outstanding stock after such tender offer or exchange offer, or (iv) the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section
9(a) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the right thereafter
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations
on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any such Fundamental
Transaction unless prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or
the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation
to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled
to purchase and/or receive (as the case may be), and the other obligations under this Warrant. The provisions of this paragraph
(c) shall similarly apply to subsequent transactions analogous to a Fundamental Transaction.

 

     4 

4817-3601-5703, v. 1

     

    

 

(c)       Certain
Issuances of Common Securities. If, any time prior to the three year anniversary of the Original Issue Date of this Warrant,
the Company shall (x) sell or issue shares of its Common Stock (other than a dividend or distribution of Common Stock referred
to in Section (a) above), (y) issue rights, options or warrants to subscribe for or purchase shares of Common Stock or (z) issue
or sell other rights for shares of Common Stock or securities convertible or exchangeable into shares of Common Stock (collectively,
any such stock, rights, options or warrants being referred to as “Common Securities”), at a price per share
less than the then applicable Exercise Price, then in each such case the Exercise Price in effect immediately prior to the issuance
of such Common Securities shall be reduced to per share price paid in respect of the issuance of such Common Securities. The adjustment
provided for in this Section (c) shall be made successively whenever any such Common Securities are issued (provided, however,
that, except as provided below, no further adjustments in the Exercise Price shall be made upon the subsequent exercise, conversion
or exchange, as applicable of such Common Securities pursuant to the terms of such Common Securities) and shall become effective
immediately after such issuance. In determining whether any Common Securities entitle the holders of the Common Stock to subscribe
for or purchase shares of Common Stock at less than the Exercise Price, and in determining the aggregate offering price of the
shares of Common Stock so offered, there shall be taken into account any consideration received by the Company for such Common
Securities, any consideration required to be paid upon the exercise, conversion, or exchange, as applicable, of such Common Securities
and the fair market value (as determined in good faith by the Company’s board of directors) of all such consideration (if
other than cash). For purposes of this Section 9(c), the number of shares of Common Stock at any time outstanding shall not include
shares held in the treasury of the Company or by any subsidiary of the Company. Notwithstanding the foregoing, no adjustment will
be made under this Section 9(c) in respect of: (i) the issuance of securities upon the exercise or conversion of any Common Stock,
or stock or securities directly or indirectly convertible into or exercisable or exchangeable for Common Stock (“Convertible
Securities”), issued by the Company prior to the date hereof and disclosed in the SEC Reports (as defined in the Purchase
Agreement); provided, however, that neither the conversion price, exercise price nor number of shares issuable under such Convertible
Securities (excluding any Convertible Securities covered by clause (ii) below) is amended, modified or changed after the Original
Issuance Date of this Warrant other than pursuant to the provisions of such Convertible Securities as they exist as of such date,
(ii) the grant of options, warrants, Common Stock or other Convertible Securities (but not including any amendments to such instruments)
to employees, officers, directors of the Company under any duly authorized Company stock option, restricted stock plan or stock
purchase plan whether now existing or hereafter approved by the Company and its stockholders in the future, and the issuance of
Common Stock in respect thereof, (iii) the grant of options, warrants, Common Stock or other Convertible Securities (but not including
any amendments to such instruments) to employees, officers, directors of the Company that are exempted from stockholder approval
under Nasdaq listing rules (such as under the exemption for inducement grants), or that would be so exempt if the Company’s
securities were listed on Nasdaq, and the issuance of Common Stock in respect thereof, or (iv) the issuance of securities in a
transaction described in paragraphs (a) and (b) of this Section.

 

        (d)
       Number of Warrant Shares. Simultaneously with any adjustment to the Exercise
Price pursuant to paragraph (a) of this Section, the number of Warrant Shares that may be purchased upon exercise of this Warrant
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder
for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately
prior to such adjustment.

 

     5 

4817-3601-5703, v. 1

     

    

 

(e)        Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable.
The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account
of the Company, and the sale or issuance of any such shares shall be considered an issue or sale of Common Stock.

 

10.        Payment of Exercise
Price. The Holder shall pay the Exercise Price in immediately available funds; provided, however, that if, on any Exercise
Date a registration statement registering the issuance or resale of the Warrant Shares under the Securities Act of 1933, as amended
(the “Securities Act”) is not effective, the Holder may, in its sole discretion, satisfy its obligation to pay
the Exercise Price through a “cashless exercise”, in which event the Company shall issue to the Holder the number of
Warrant Shares determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

X = the number of Warrant Shares to be issued to the Holder.

 

Y = the total number of Warrant Shares with respect to which this Warrant
is being exercised.

 

A = the average of the Closing Sale Prices of the shares of Common Stock (as
reported by Bloomberg Financial Markets) for the five Trading Days ending on the date immediately preceding the Exercise Date.

 

B = the Exercise Price then in effect for the applicable Warrant Shares at
the time of such exercise.

 

For purposes of this Warrant, “Closing Sale Price”
means, for any security as of any date, the last trade price for such security on the principal securities exchange or trading
market for such security, as reported by Bloomberg Financial Markets, or, if such exchange or trading market begins to operate
on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00:00
p.m., New York Time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such
security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets,
or, if no last trade price is reported for such security by Bloomberg Financial Markets, the average of the bid prices, or the
ask prices, respectively, of any market makers for such security as reported in the "pink sheets" by Pink Sheets LLC.
If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale
Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the
Company and the Holder are unable to agree upon the fair market value of such security, then the Company shall, within two business
days submit via facsimile (a) the disputed determination of the Warrant Exercise Price to an independent, reputable investment
bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the
Company's independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the
case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten
business days from the time it receives the disputed determinations or calculations. Such investment bank's or accountant's determination
or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. All such determinations to be
appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable
calculation period

 

     6 

4817-3601-5703, v. 1

     

    

 

For purposes of Rule 144 promulgated under the Securities Act, it
is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to have
been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this
Warrant was originally issued pursuant to the Purchase Agreement (provided that the Commission continues to take the position that
such treatment is proper at the time of such exercise).

 

11.        Limitations on
Exercise. (a) Notwithstanding anything to the contrary contained herein, the number of Warrant Shares that may be acquired
by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure
that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by the Holder
and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s
for purposes of Section 13(d) of the Exchange Act, does not exceed 4.999% of the total number of issued and outstanding shares
of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise). For such purposes, beneficial
ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
Each delivery of an Exercise Notice by the Holder will constitute a representation by the Holder that it has evaluated the limitation
set forth in this Section and determined that issuance of the full number of Warrant Shares requested in such Exercise Notice is
permitted under this Section. The Company’s obligation to issue shares of Common Stock in excess of the limitation referred
to in this Section shall be suspended (and, except as provided below, shall not terminate or expire notwithstanding any contrary
provisions hereof) until such time, if any, as such shares of Common Stock may be issued in compliance with such limitation; provided,
that, if, as of 4:30 p.m., prevailing Minneapolis time, on the Expiration Date, the Company has not received written notice that
the shares of Common Stock may be issued in compliance with such limitation, the Company’s obligation to issue such shares
shall terminate. This provision shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially
own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental
Transaction as contemplated in Section 9 of this Warrant. By written notice to the Company, the Holder may waive the provisions
of this Section but any such waiver will not be effective until the 61st day after such notice is delivered to the Company,
nor will any such waiver effect any other Holder.

 

        (b)       Notwithstanding
anything to the contrary contained herein, the number of Warrant Shares that may be acquired by the Holder upon any exercise of
this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure that, following such exercise
(or other issuance), the total number of shares of Common Stock then beneficially owned by such Holder and its Affiliates and any
other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d)
of the Exchange Act, does not exceed 9.999% of the total number of issued and outstanding shares of Common Stock (including for
such purpose the shares of Common Stock issuable upon such exercise). For such purposes, beneficial ownership shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Each delivery of an
Exercise Notice hereunder will constitute a representation by the Holder that it has evaluated the limitation set forth in this
Section and determined that issuance of the full number of Warrant Shares requested in such Exercise Notice is permitted under
this Section. The Company’s obligation to issue shares of Common Stock in excess of the limitation referred to in this Section
shall be suspended (and, except as provided below, shall not terminate or expire notwithstanding any contrary provisions hereof)
until such time, if any, as such shares of Common Stock may be issued in compliance with such limitation; provided, that, if, as
of 4:30 p.m., prevailing City time, on the Expiration Date, the Company has not received written notice that the shares of Common
Stock may be issued in compliance with such limitation, the Company’s obligation to issue such shares shall terminate. This
provision shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated
in Section 9 of this Warrant. This restriction may not be waived.

 

     7 

4817-3601-5703, v. 1

     

    

 

12.        No Fractional Shares.
No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which
would otherwise be issuable, subject to Section 11, the number of Warrant Shares to be issued shall be rounded up to the next whole
number.

 

13.        Notices. Any
and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in
writing and shall be mailed (registered or certified mail, return receipt requested), or personally delivered and shall be deemed
given when so delivered or if mailed, two (2) days after such mailing, in each case to the address specified in the Purchase Agreement.

 

14.        Warrant Agent.
The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the Company may
appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting
from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or
any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession
as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown
on the Warrant Register.

 

15.        Miscellaneous.

 

(a)               
The Holder, solely in such Person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or
be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed
to confer upon the Holder, solely in such Person's capacity as the Holder of this Warrant, any of the rights of a stockholder of
the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the
Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 15(a),
the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company,
contemporaneously with the giving thereof to the shareholders.

 

     8 

4817-3601-5703, v. 1

     

    

 

(b)              
Subject to the restrictions on transfer set forth on the first page hereof and in Section 4.1 of the Purchase Agreement, and compliance
with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company except
to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the parties
hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed
to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this
Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. 

 

(c)               
GOVERNING LAW; VENUE; WAIVER OF JURY TRIAL. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION
OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF MINNESOTA WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE CITY OF MINNEAPOLIS, MINNESOTA AND HENNEPIN COUNTY, MINNESOTA, FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO
THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION
OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING
IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH
SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD
AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO
SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. 

 

(d)        The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

 

(e)        In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

     9 

4817-3601-5703, v. 1

     

    

 

(f)        Except
as otherwise set forth herein, prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a Holder,
be entitled to any rights of a stockholder with respect to the Warrant Shares.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

 

 

 

 

     10 

4817-3601-5703, v. 1

     

    

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.

 

	 	 	 
	 	SKYLINE MEDICAL INC
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

 

 

 

 

     11 

4817-3601-5703, v. 1

     

    

 

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder to exercise the right to purchase shares

of Common Stock under the foregoing Warrant)

 

To: Skyline Medical Inc.

 

(1)       The undersigned is
the Holder of Warrant No. __________ (the “Warrant”) issued by Skyline Medical Inc. a Delaware corporation (the “Company”).
Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

 

(2)       The undersigned hereby
exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.

  

(3)       The Holder intends
that payment of the Exercise Price shall be made as (check one):

 

☐       Cash
Exercise

 

☐       “Cashless
Exercise” under Section 10

 

(4)       If the Holder has elected
a Cash Exercise, the Holder shall pay the sum of $_______ in immediately available funds to the Company in accordance with the
terms of the Warrant.

 

(5)       Pursuant to this Exercise
Notice, the Company shall deliver to the Holder _____________ Warrant Shares in accordance with the terms of the Warrant.

 

(6)       By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby, the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance
with Section 13(d) of the Securities Exchange Act of 1934) permitted to be owned under Section 11 of the Warrant to which this
notice relates.

 

Dated:_______________, _____

 

	Name of Holder: 	 	 

 

	By:	 	 
	Name: 		 
	Title: 	 	 

 

(Signature must conform in all respects to name of

Holder as specified on the face of the Warrant)

 

     

4817-3601-5703, v. 1

     

    

 

SCHEDULE 2

 

SKYLINE MEDICAL INC.

 

FORM OF ASSIGNMENT

 

[To be completed and signed only upon transfer of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto                             
(the “Transferee” the right represented by the within Warrant to purchase                 
shares of Common Stock of Skyline Medical Inc. (the “Company”) to which the within Warrant relates and appoints                             
attorney to transfer said right on the books of the Company with full power of substitution in the premises. In connection therewith,
the undersigned represents, warrants, covenants and agrees to and with the Company that:

 

		(a)	the offer and sale of the Warrant contemplated hereby is being made in compliance with Section
4(1) of the United States Securities Act of 1933, as amended (the “Securities Act”) or another valid exemption from
the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states
of the United States;

 

		(b)	the undersigned has not offered to sell the Warrant by any form of general solicitation or general
advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper,
magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by
any general solicitation or general advertising;

 

		(c)	the undersigned has read the Transferee’s investment letter included herewith, and to its
actual knowledge, the statements made therein are true and correct; and

 

		(d)	the undersigned understands that the Company may condition the transfer of the Warrant contemplated
hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel
(which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect
that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states
of the United States.

 

Dated:_______________, _____

 

		 	
         

        

	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
	 	 	
         

        

	 	 	 
	 	 	Address of Transferee
	 	 	
         

        

	 	 	
         

        

	 	 	 
	 	 	 

 

In the presence of:

 

	 	 	 

 

 

 

 

 

4817-3601-5703, v. 1Exhibit 10.1

 

Execution Version

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (the
“Agreement”), dated as of November 28, 2017 (the “Execution Date”), among Skyline Medical
Inc., a Delaware corporation (the “Company”), and the investor listed on the Buyer Schedule attached hereto
(“Buyer”).

 

RECITALS

 

A.       The
Company and Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506 of Regulation D
(“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act.

 

B.       Buyer
wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) Series C convertible
preferred stock of the Company (the “Series C Preferred Shares”) convertible into shares of common stock of
the Company (the “Common Stock” and such shares of Common Stock issuable upon conversion of the Series C Preferred
Shares, the “Conversion Shares”), as further specified herein, set forth on the Buyer Schedule, with the terms
and rights set forth on the Certificate of Designation (the “Certificate of Designation”) in the form attached
hereto as Exhibit A, and (ii) warrants to initially acquire up to the aggregate of up to number of shares of Common
Stock set forth on the Buyer Schedule, in the form attached hereto as Exhibit B (the “Warrants”)
(as exercised, collectively, the “Warrant Shares”).

 

C.       At
the Closing (as defined below), the parties hereto shall execute and deliver a Registration Rights Agreement, in the form attached
hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company has agreed
to provide certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement),
under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

 

D.       The
Series C Preferred Shares, the Conversion Shares, the Warrants and the Warrant Shares are collectively referred to herein as the
“Securities.”

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises
and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Company and Buyer hereby agree as follows:

 

		1.	PURCHASE AND SALE OF PREFERRED STOCK AND WARRANTS.

 

		(a)	Preferred Stock and Warrants. Subject to the satisfaction (or waiver) of the conditions
set forth in Sections 6 and 7 below, the Company shall issue and sell to Buyer, and Buyer shall purchase from the Company on the
Closing Date (as defined below), the number of Series C Preferred Shares at such Closing Date as is set forth on the Buyer Schedule,
along with Warrants to initially acquire up to the aggregate number of Warrant Shares as is set forth on the Buyer Schedule.

 

 

    
DM_US 86580026-11.096039.0012

     

    

 

(b)              
Closing. The closing (the “Closing”) of the purchase of the Series C Preferred Shares and the
Warrants by the Buyer as contemplated by this Agreement shall occur at the offices of McDermott, Will & Emery LLP, 340 Madison
Avenue, New York, New York 10017. The date and time of the Closing (the applicable “Closing Date”) shall be
10:00 a.m., New York time, on the first (1st) Business Day on which the conditions to such Closing set forth in Sections
6 and 7 below are satisfied or waived (or such later date as is mutually agreed to by the Company and Buyer). As used herein “Business
Day” means any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required by law to remain closed. Subject to the conditions set forth in this Agreement and the termination provisions hereof,
the Closing shall be held on the Execution Date.

 

(c)              
Purchase Price. The aggregate purchase price for the Series C Preferred Shares and the Warrants to be purchased by
Buyer (the applicable “Purchase Price”) shall be paid at the Closing and in the applicable amount as set forth
on the Buyer Schedule.

 

(d)             
Payment of Purchase Price; Delivery of Securities. On the Closing Date, (i) Buyer shall pay the applicable Purchase
Price to the Company for the respective Securities to be issued and sold to Buyer at the Closing, by wire transfer of immediately
available funds in accordance with the Company’s written wire instructions and (ii) the Company shall issue to Buyer (A)
the Series C Preferred Shares, to be issued at such Closing (as set forth on the Buyer Schedule) and (B) the Warrants as set forth
on the Buyer Schedule (pursuant to which Buyer shall have the right to acquire up to the aggregate number of Warrant Shares as
is set forth on the Buyer Schedule in respect of such Warrants), in all cases, duly executed on behalf of the Company and registered
in the name of Buyer or its designee, all as set forth on the Buyer Schedule.

 

(e)               
Maximum Shares. Notwithstanding anything in this Agreement to the contrary, the total number of Conversion Shares
that may be issued to Buyer, shall be limited to 1,250,269 shares of Common Stock, which is 19.9% of the issued and outstanding
shares of Common Stock as of the date of this Agreement (the “Maximum Shares”). The Maximum Shares shall be
appropriately adjusted for any stock dividend, stock split, reverse stock split or similar transaction. Notwithstanding the foregoing,
the Company shall not be required or permitted to issue, and the Buyer shall not be required to purchase, any shares of Common
Stock under this Agreement if such issuance would violate the rules or regulations of the Principal Market.

 

(f)               
Beneficial Ownership Limitation. Except as set otherwise forth in the Certificate of
Designation or the Warrants, the Company shall not issue and Buyer shall not purchase any shares of Common Stock under this Agreement
if such shares proposed to be issued and sold, when aggregated with all other shares of Common Stock then owned beneficially (as
calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) by Buyer and its Affiliates (as
defined in Section 3(f)) would result in the beneficial ownership by Buyer and its Affiliates of more than the “Maximum Percentage”
(as defined in the Certificate of Designation or the Warrants, as the case may be), of the then issued and outstanding shares of
Common Stock.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		2.	BUYER’S REPRESENTATIONS AND WARRANTIES.

 

Buyer represents and warrants to the Company
that:

 

(a)               
Organization; Authority. Buyer is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents (as defined below) to which it is a party and otherwise to carry out its obligations
hereunder and thereunder.

 

(b)              
No Public Sale or Distribution. Buyer (i) is acquiring the Series C Preferred Shares and the Warrants, (ii) upon
conversion of the Series C Preferred Shares will acquire the Conversion Shares issuable upon conversion thereof, and (iii) upon
exercise of its Warrants will acquire the Warrant Shares issuable upon exercise thereof, in each case, for its own account and
not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities
laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by making the representations
herein, Buyer does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific
term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement
or an exemption under the 1933 Act. Buyer does not presently have any agreement or understanding, directly or indirectly, with
any Person (as defined below) to distribute any of the Securities in violation of applicable securities laws.

 

(c)               
Accredited Investor Status. Buyer is an “accredited investor” as that term is defined in Rule 501(a)
of Regulation D.

 

(d)              
Reliance on Exemptions. Buyer understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of Buyer
to acquire the Securities.

 

(e)               
Information. Buyer and its advisors, if any, acknowledge that they have been furnished with or provided access via
EDGAR to the Company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form
8-K, if any. Buyer and its advisors, if any, have been afforded the opportunity to ask questions of, and receive answers from,
the Company concerning the offer and sale of the Securities and to obtain any additional information Buyer has requested which
is necessary to verify the accuracy of the information furnished to Buyer concerning the Company and such offering. Buyer understands
that its investment in the Securities involves a high degree of risk. Buyer has sought such accounting, legal and tax advice as
it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities. Buyer acknowledges
that Buyer is basing its decision to invest in the Securities solely upon the information contained in the Transaction Documents,
the Company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, if
any, and its own due diligence and, except as specifically set forth in this Agreement, has not based its investment decision upon
any representations made by any Person (as defined below).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(f)               
No Governmental Review. Buyer understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of
the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)              
Transfer or Resale. Buyer understands that except as provided in the Registration Rights Agreement and Section 4(h)
hereof: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may
not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) Buyer shall have delivered
to the Company (if requested by the Company) an opinion of counsel to Buyer, in a form reasonably acceptable to the Company, to
the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption
from such registration, or (C) Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned
or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule
144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of
Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or
the Person (as defined below) through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the
1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated
thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the 1933
Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder.

 

(h)              
Validity; Enforcement(i). The execution and delivery of the Transaction Documents and the consummation by Buyer
of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary action on the part
of Buyer and no further consent or authorization of Buyer or its members is required. Each Transaction Document has been duly
executed by Buyer and when delivered in accordance with terms hereof and thereof, constitutes the legal, valid and binding obligations
of Buyer enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or
affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(j)                
No Conflicts. The execution, delivery and performance by Buyer of this Agreement and the consummation by Buyer of
the transactions contemplated hereby will not (i) result in a violation of the organizational documents of Buyer, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which Buyer
is a party or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state
securities laws) applicable to Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights
or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the
ability of Buyer to perform its obligations hereunder.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(k)              
Certain Trading Activities. Buyer has not directly or indirectly, nor has any Person (as defined below) acting on
behalf of or pursuant to any understanding with Buyer, engaged in any transactions in the securities of the Company (including,
without limitation, any Short Sales (as defined below) involving the Company’s securities) during the period commencing as
of the time that the Buyer and Company first began discussions regarding the specific investment in the Company contemplated by
this Agreement and ending immediately prior to the execution of this Agreement (it being understood and agreed that for all purposes
of this Agreement, and without implication that the contrary would otherwise be true, that neither transactions nor purchases nor
sales shall include the location and/or reservation of borrowable shares of Common Stock). “Short Sales” means
all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934,
as amended (the “1934 Act”).

 

(l)                
Experience of Buyer. Buyer has such knowledge, sophistication and experience in business and financial matter so
as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits
and risks of such investment. Buyer is able to bear the economic risk of an investment in the Securities and, at the present time,
is able to afford a complete loss of such investment.

 

(m)            
General Solicitation. Buyer is not purchasing the Securities as a result of any advertisement, article, notice or
other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar or any other general solicitation or advertisement.

 

		3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company represents and warrants to Buyer
the matters set forth in this Section 3, as may be qualified by the corresponding section of the Company Disclosure Schedule. These
representations and warranties, and the information set forth in the Company Disclosure Schedule, are current as of the date of
this Agreement, except to the extent that a representation, warranty or section of the Company Disclosure Schedule expressly states
that such representation or warranty, or information in such section of the Company Disclosure Schedule, is currently only as of
an earlier date. If any information is so reflected as of an earlier date, there have been no material changes since such date
to the date hereof.

 

(a)               
Organization and Qualification. Each of the Company and each of its subsidiaries (as defined below) are entities
duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have
the requisite corporate power and authorization to own their properties and to carry on their business as now being conducted and
as presently proposed to be conducted. Each of the Company and each of its subsidiaries is duly qualified as a foreign entity to
do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted
by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would
not have a Material Adverse Effect. “Material Adverse Effect” means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the
Company and its subsidiaries, taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents
or (iii) the authority or ability of the Company to perform any of its obligations under any of the Transaction Documents (as defined
below). The Company has no material subsidiaries. There are no rights or liabilities or obligations (contingent or otherwise) of
any of the subsidiaries.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(b)              
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with
the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents by the Company and
the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance
of the Preferred Shares and the Warrants and the reservation for issuance and issuance of the Conversion Shares, issuable upon
conversion of the Series C Preferred Shares, and the issuance of the Warrant Shares and the reservation for issuance and issuance
of the Warrant Shares issuable upon exercise of the Warrants) have been duly authorized by the Company’s board of directors
and (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements of the Registration
Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies, the filing of
requisite notice and/or application to the Principal Market for the issuance and sale of the Securities and the filings required
by Section 4(i) of this Agreement) no further filing, consent or authorization is required by the Company, its board of directors
or its stockholders or other governing body of the Company. This Agreement has been, and the other Transaction Documents will be
prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification
and to contribution may be limited by federal or state securities law. “Transaction Documents” means, collectively,
this Agreement, the Warrants, the Certificate of Designation, and each of the other agreements and instruments entered into or
delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from
time to time.

 

(c)               
Issuance of Securities. The issuance of the Series C Preferred Shares and the Warrants are duly authorized and, upon
issuance in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and non-assessable and free
from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof. As of the
Closing, the Company shall have reserved from its duly authorized capital stock not less than the sum of (i) 150% of the maximum
number of Conversion Shares issuable upon conversion of the Series C Preferred Shares (assuming for purposes hereof that the Series
C Preferred Shares are convertible at the Conversion Price (as defined in the Buyer Schedule and without taking into account any
limitations on the conversion of the Series C Preferred Shares set forth therein) and (ii) 150% of the maximum number of Warrant
Shares issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set
forth therein). The issuance of the Conversion Shares is duly authorized, and upon conversion in accordance with the Certificate
of Designation, the Conversion Shares, when issued, will be validly issued, fully paid and non-assessable and free from all preemptive
or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled
to all rights accorded to a holder of Common Stock. The issuance of the Warrant Shares is duly authorized, and upon exercise in
accordance with the Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and non-assessable and free from
all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders
being entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties
of the Buyer in this Agreement, the offer and issuance by the Company of the Securities is exempt from registration under the 1933
Act. Buyer will have good and marketable title to the Securities.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(d)              
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Series C
Preferred Shares, the Warrants, the Conversion Shares and Warrant Shares and the reservation for issuance of the Conversion Shares
and Warrant Shares) will not (i) result in a violation of the Certificate of Incorporation (as defined below) (including, without
limitation, any certificate of designation contained therein) or other organizational documents of the Company, any capital stock
of the Company or Bylaws (as defined below) of the Company, (ii) conflict with, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company is a party or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and
regulations and the rules and regulations of the Nasdaq Capital Market (the “Principal Market”) applicable to
the Company or by which any property or asset of the Company is bound or affected except, in the case of clause (ii) or (iii) above,
to the extent such violations that could not reasonably be expected to have a Material Adverse Effect.

 

(e)               
Consents. The Company is not required to obtain any consent from, authorization or order of, or make any filing or
registration with (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements
of the Registration Rights Agreement, a Form D with the SEC and other filings as may be required by any state securities agencies,
the filing of requisite notice and/or application to the Principal Market for the issuance and sale of the Securities and the filings
required by Section 4(i) of this Agreement), any court, governmental agency or any regulatory or self-regulatory agency or any
other Person in order for it to execute, deliver or perform any of its respective obligations under, or contemplated by, the Transaction
Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations
which the Company is required to obtain at or prior to the Closing have been obtained or effected on or prior to the Closing Date,
and the Company is not aware of any facts or circumstances which might prevent the Company from obtaining or effecting any of the
registration, application or filings contemplated by the Transaction Documents. The Company is not in violation of the requirements
of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to suspension of the Common
Stock in the foreseeable future. There is no requirement for the Company to obtain approval of the Principal Market for listing
or trading of Registrable Securities which constitute Common Stock.

 

(f)               
Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that Buyer is
acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby and that Buyer is not (i) an officer or director of the Company, (ii) an “Affiliate”
(as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers, directors and holders of at
least 10% of the Company’s issued and outstanding Common Stock are Affiliates without conceding that any such Persons are
“affiliates” for purposes of federal securities laws) or (iii) to its knowledge, a “beneficial owner” of
more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges
that Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated hereby and thereby, and any advice given by Buyer or any of its representatives or
agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to
Buyer’s purchase of the Securities. The Company further represents to Buyer that the Company’s decision to enter into
the Transaction Documents to which it is a party has been based solely on the independent evaluation by the Company and its representatives.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(g)                 
No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any placement agent’s
fees, financial advisory fees, or brokers’ commissions, relating to or arising out of the transactions contemplated hereby.

 

(h)              
No Integrated Offering. None of the Company or any of its subsidiaries, nor, to the knowledge of the Company, any
Person acting on its behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy
any security, under circumstances that would require registration of the issuance of any of the Securities under the 1933 Act,
whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of
stockholders of the Company under any applicable stockholder approval provisions, including, without limitation, under the rules
and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated
for quotation. None of the Company, its subsidiaries nor, to the knowledge of the Company, any Person acting on its behalf will
take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act or cause the
offering of any of the Securities to be integrated with other offerings of securities of the Company.

 

(i)                
Dilutive Effect. The Company understands and acknowledges that the number of Conversion Shares and Warrant Shares
may increase in certain circumstances. The Company further acknowledges that, except in case where an issuance would exceed the
beneficial ownership limitation in Section 1(e) of this Agreement, its obligation to issue the Conversion Shares upon conversion
of the Series C Preferred Shares and the Warrant Shares upon exercise of the Warrants in accordance with this Agreement, the Series
C Preferred Shares and the Warrants is absolute and unconditional, regardless of the dilutive effect that such issuance may have
on the ownership interests of other stockholders of the Company.

 

(j)                
Application of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under
the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation
or otherwise which is or could become applicable to Buyer as a result of the transactions contemplated by this Agreement, including,
without limitation, the Company’s issuance of the Securities and Buyer’s ownership of the Securities. The Company and
its board of directors have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or
similar arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(k)              
SEC Documents; Financial Statements. During the two (2) years prior to the date hereof, the Company has timely filed
all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting
requirements of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits and appendices included therein
and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred
to as the “SEC Documents”). As of their respective dates, the SEC Documents complied in all material respects
with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company
included in the SEC Documents complied in all material respects with applicable accounting requirements and the published rules
and regulations of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared
in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may
be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements,
to the extent they may exclude the footnotes or may be condensed or summary statements) and fairly present in all material respects
the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either
individually or in the aggregate). No other information provided by or on behalf of the Company to Buyer which is not included
in the SEC Documents contains any untrue statement of a material fact or omits to state any material fact necessary in order to
make the statements therein not misleading, in the light of the circumstance under which they are or were made.

 

(l)                
Absence of Certain Changes. Since the date of the Company’s most recent audited financial statements contained
in a Form 10-K, except as disclosed in the SEC Documents filed subsequent to such Form 10-K, there has been no material adverse
change and no material adverse development in the business, assets, liabilities, properties, operations (including results thereof),
condition (financial or otherwise) or prospects of the Company. Since the date of the Company’s most recent audited financial
statements contained in a Form 10-K, the Company has not (i) declared or paid any dividends, (ii) sold any material assets outside
of the ordinary course of business or (iii) made any material capital expenditures, individually or in the aggregate, outside of
the ordinary course of business. The Company has not taken any steps to seek protection pursuant to any law or statute relating
to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company have any knowledge or
reason to believe that any of its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any
fact which would reasonably lead a creditor to do so. The Company is not, and after giving effect to the transactions contemplated
hereby to occur at the Closing will not be, Insolvent (as defined below). “Insolvent” means, (A) the present
fair saleable value of the Company’s assets is less than the amount required to pay the Company’s total Indebtedness
(as defined below), (B) the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such
debts and liabilities become absolute and matured or (C) the Company intends to incur or believes that it will incur debts that
would be beyond its ability to pay as such debts mature. The Company has not engaged in any business or in any transaction, and
is not about to engage in any business or in any transaction, for which the Company’s remaining assets constitute unreasonably
small capital.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(m)            
No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance
has occurred or exists, or is reasonably expected to occur or exist with respect to the Company or any of its businesses, properties,
liabilities, prospects, operations (including results thereof) or condition (financial or otherwise) that to the Company’s
knowledge, would have a material effect on Buyer’s investment hereunder.

 

(n)              
Conduct of Business; Regulatory Permits. The Company is not in violation of any term of or in default under its Certificate
of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the
Company or Bylaws or their organizational charter, certificate of formation or certificate of incorporation or bylaws, respectively.
The Company is not in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the
Company, and the Company will not conduct its business in violation of any of the foregoing, except in all cases for possible violations
which could not, individually or in the aggregate, have a Material Adverse Effect. Without limiting the generality of the foregoing,
except as disclosed in the SEC Documents, the Company is not in violation of any of the rules, regulations or requirements of the
Principal Market and has no knowledge of any facts or circumstances that could reasonably lead to suspension of the Common Stock
by the Principal Market in the foreseeable future. Since January 1, 2015, (i) the Common Stock has been designated for quotation
on the Principal Market, (ii) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) except
as disclosed in the SEC Documents, the Company has received no communication, written or oral, from the SEC or the Principal Market
regarding the suspension of the Common Stock from the Principal Market. The Company possesses all certificates, authorizations
and permits issued by the appropriate regulatory authorities necessary to conduct its businesses, except where the failure to possess
such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and the
Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization
or permit.

 

(o)              
Foreign Corrupt Practices. Neither the Company nor any of its subsidiaries nor to the knowledge of the Company, any
director, officer, agent, employee or other Person acting on behalf of the Company or any of its subsidiaries (as applicable) has,
in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect
unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation
of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff,
influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(p)              
Sarbanes-Oxley Act. Except as set forth in the SEC Documents, the Company is in material compliance with all applicable
requirements of the Sarbanes-Oxley Act of 2002 and all applicable rules and regulations promulgated by the SEC thereunder.

 

(q)              
Transactions With Affiliates. Except as disclosed in the SEC Documents, none of the officers, directors, employees
or Affiliates of the Company is presently a party to any transaction with the Company (other than for ordinary course services
as employees, officers or directors and immaterial transactions), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any such officer, director, employee or Affiliate or, to the knowledge of the Company, any corporation, partnership,
trust or other Person in which any such officer, director, employee or Affiliate has a substantial interest or is an employee,
officer, director, trustee or partner.

 

(r)                
Equity Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (i) 24,000,000
shares of Common Stock, of which, 6,282,761 are issued and outstanding and 4,022,844 shares
are reserved for issuance pursuant to Convertible Securities (as defined below) (other than the Series C Preferred Shares and the
Warrants), and (ii) 20,000,000 shares of preferred stock, of which 0 are Series A Convertible Preferred Stock issued and outstanding
and 79,246 are Series B Convertible Preferred Stock issued and outstanding. No shares of Common Stock are held in treasury. All
of such outstanding shares of Common Stock are duly authorized and have been, or upon issuance will be, validly issued and are
fully paid and non-assessable. 66,483 shares of the Company’s issued and outstanding Common Stock, as of November 13, 2017,
are owned by Persons who are Affiliates of the Company. Except as disclosed in the SEC Documents: (i) to the Company’s knowledge,
no Person owns 10% or more of the Company’s issued and outstanding shares of Common Stock (calculated based on the assumption
that all Convertible Securities, whether or not presently exercisable or convertible, have been fully exercised or converted (as
the case may be) taking account of any limitations on exercise or conversion (including “blockers”) contained therein
without conceding that such identified Person is a 10% stockholder for purposes of federal securities laws); (ii) the Company’s
capital stock is not subject to preemptive rights or any other similar rights or any liens or encumbrances; (iii) there are no
outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company, or contracts, commitments,
understandings or arrangements by which the Company is or may become bound to issue additional capital stock of the Company or
options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or
rights convertible into, or exercisable or exchangeable for, any capital stock of the Company (other than as may be issued from
time to time under any equity incentive plan maintained); (iv) there are no outstanding debt securities, credit agreements, credit
facilities or other agreements, documents or instruments evidencing Indebtedness of the Company or by which the Company is or may
become bound; (v) there are no financing statements securing obligations in any amounts filed in connection with the Company; (vi)
there are no agreements or arrangements under which the Company is obligated to register the sale of any of their securities under
the 1933 Act (except pursuant to the Registration Rights Agreement); (vii) there are no outstanding securities or instruments of
the Company which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which the Company is or may become bound to redeem a security of the Company; (viii) there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (ix) the Company has no
stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; and (x) the Company
does not have any liabilities or obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC
Documents, other than those incurred in the ordinary course of the Company’s business and which does not or could not have
a Material Adverse Effect. The SEC Documents contain true, correct and complete copies of the Company’s Certificate of Incorporation,
as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s
bylaws, as amended and as in effect on the date hereof (the “Bylaws”), and the terms of all securities convertible
into, or exercisable or exchangeable for, shares of Common Stock and the material rights of the holders thereof.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(s)               
Indebtedness and Other Contracts. Except as disclosed in the SEC Documents, the Company (i) does not have any material
outstanding Indebtedness or other material obligations, (ii) is not a party to any contract, agreement or instrument, the violation
of which, or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected
to result in a Material Adverse Effect, (iii) is not in violation of any term of, or in default under, any contract, agreement
or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the
aggregate, in a Material Adverse Effect, and (iv) is not a party to any contract, agreement or instrument relating to any Indebtedness,
the performance of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect.
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

 

(t)                
Absence of Litigation. Except as disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or
investigation before or by the Principal Market, any court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock or any of the Company’s
executive officers or directors which would be reasonably likely to adversely affect the transactions contemplated by this Agreement
or would require disclosure in the SEC Documents, except as otherwise disclosed in the SEC Documents. There has not been, and to
the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any current
or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company under the 1933 Act or the 1934 Act.

 

(u)              
Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company is
engaged. The Company has not been refused any insurance coverage sought or applied for, and the Company has no reason to believe
that it will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(v)              
Employee Relations. The Company is not a party to any collective bargaining agreement nor does it employ any member
of a union. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company
has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment
with the Company. To the knowledge of the Company, no executive officer or other key employee of the Company is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each
such executive officer or other key employee (as the case may be) does not subject the Company to any liability with respect to
any of the foregoing matters. The Company is in compliance with all federal, state, local and foreign laws and regulations respecting
labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure
to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect.

 

(w)            
Title. The Company has good and marketable title to (i) all real property owned by it and (ii) all personal property,
owned by it which is material to the business of the Company, in each case, free and clear of all liens, encumbrances and defects
except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made
of such property by the Company. Any real property and facilities held under lease by the Company are held by it under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made
of such property and buildings by the Company.

 

(x)              
Intellectual Property Rights. The Company owns or possesses adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct its businesses as now conducted
and as presently proposed to be conducted. None of the Company’s Intellectual Property Rights have expired, terminated or
been abandoned, or are expected to expire, terminate or be abandoned, within three years from the date of this Agreement, which
could reasonably be expected to result in a Material Adverse Effect. The Company has no knowledge of any material infringement
by the Company of Intellectual Property Rights of others, except as disclosed in the SEC Documents. There is no claim, action or
proceeding being made or brought, or to the knowledge of the Company, being threatened, against the Company regarding its Intellectual
Property Rights and which would reasonably be expected to have a Material Adverse Effect, except as disclosed in the SEC Documents.
The Company is not aware of any facts or circumstances which might give rise to any of the foregoing infringements or claims, actions
or proceedings. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of
its Intellectual Property Rights, except where failure to take such measures would not, either individually or in the aggregate,
reasonably be expected to materially affect the value of its Intellectual Property Rights.

 

(y)              
Environmental Laws. The Company (i) is in compliance with all Environmental Laws (as defined below), (ii) has received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct its businesses and (iii)
is in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses
(i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect. “Environmental Laws” means all federal, state, local or foreign laws relating to pollution or
protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface
or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of
chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(z)               
Tax Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected
to result in a material tax liability, the Company (i) has timely made or filed all foreign, federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations,
except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports or declarations apply and except in each case where
the failure to file, pay or set aside could not be reasonably expected to have a Material Adverse Effect.. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know
of no basis for any such claim. The Company is not operated in such a manner as to qualify as a passive foreign investment company,
as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended.

 

(aa)           
Internal Accounting and Disclosure Controls. Except as disclosed in the SEC Documents, the Company maintains internal
control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles, including that (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles and to maintain asset and liability accountability, (iii) access to assets
or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv)
the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals
and appropriate action is taken with respect to any difference. The Company maintains disclosure controls and procedures (as such
term is defined in Rule 13a-15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed
by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within
the time periods specified in the rules and forms of the SEC, including, without limitation, controls and procedures designed to
ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated
and communicated to the Company’s management, including its principal executive officer or officers and its principal financial
officer or officers, as appropriate, to allow timely decisions regarding required disclosure. The Company has not received any
notice or correspondence from any accountant or other Person relating to any potential material weakness or significant deficiency
in any part of the internal controls over financial reporting of the Company. There are no material disagreements presently existing,
or reasonably anticipated by the Company to arise, between the accountants and lawyers formerly or presently employed by the Company.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(bb)          
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and
an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in the SEC Documents and is
not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(cc)           
Investment Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an
“investment company,” an affiliate of an “investment company,” a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for,
an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(dd)         
Acknowledgement. The Company acknowledges that sales of shares of Common Stock by Buyer following the effectiveness
of the Registration Statement or pursuant to Rule 144 or otherwise pursuant to an exemption from registration may reduce the price
of the Common Stock. None of the foregoing shall constitute a breach of this Agreement or any other obligation of Buyer.

 

(ee)           
Manipulation of Price. The Company has not, and, to the knowledge of the Company, no Person acting on its behalf
has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid
any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation
for soliciting another to purchase any other securities of the Company.

 

(ff)            
U.S. Real Property Holding Corporation. The Company is not, has and has not ever been, and so long as any of the
Securities are held by Buyer, shall not become, a U.S. real property holding corporation within the meaning of Section 897 of the
Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Buyer’s request.

 

(gg)          
Registration Eligibility. The Company is, and on the date of filing of the Registration Statement (as defined in
the Registration Rights Agreement) will be, eligible to register the resale of the Securities by Buyer on Form S-3.

 

(hh)          
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which
are required to be paid in connection with the issuance, sale and transfer of the Securities to be sold to Buyer hereunder will
be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied
with.

 

(ii)              
Bank Holding Company Act. The Company is not subject to the Bank Holding Company Act of 1956, as amended (the “BHCA”)
and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”). Neither the
Company nor any of its affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares
of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any equity that is subject
to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its affiliates exercises a controlling influence
over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(jj)             Shell
Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

(kk)          
Public Utility Holding Act. The Company is not a “holding company,” or an “affiliate” of
a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(ll)             Federal
Power Act. The Company is not subject to regulation as a “public utility” under the Federal Power Act, as amended.

 

(mm)         Illegal
or Unauthorized Payments; Political Contributions. Neither the Company nor, to the best of the Company’s knowledge (after
reasonable inquiry of its executive officers and directors), any of the officers, directors, employees, agents or other representatives
of the Company or any other business entity or enterprise with which the Company is or has been affiliated or associated, has,
directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in
contravention of applicable law, (a) as a kickback or bribe to any Person or (b) to any political organization, or the holder
of or any aspirant to any elective or appointive public office except for personal political contributions not involving the direct
or indirect use of funds of the Company.

 

(nn)          
Money Laundering. The Company is in compliance with, and have not previously violated, the USA Patriot Act of 2001
and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the laws,
regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, without
limitation, (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With
Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained
in 31 CFR, Subtitle B, Chapter V.

 

(oo)          
Registration Rights. Except as disclosed in the SEC Documents, no holder of securities of the Company has rights
to the registration of any securities of the Company because of the filing of the Registration Statement or the issuance of the
Securities hereunder that could expose the Company to material liability or Buyer to any liability or that could impair the Company’s
ability to consummate the issuance and sale of the Securities in the manner, and at the times, contemplated hereby, which rights
have not been waived by the holder thereof as of the date hereof.

 

(pp)          
Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided Buyer or
their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public
information concerning the Company, other than the existence of the transactions contemplated by this Agreement and the other Transaction
Documents. The Company understands and confirms that Buyer will rely on the foregoing representations in effecting transactions
in securities of the Company. All disclosure provided to the Buyer regarding the Company, its business and the transactions contemplated
hereby, including the schedules to this Agreement, furnished by or on behalf of the Company is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each press release
issued by the Company during the twelve (12) months preceding the date of this Agreement did not at the time of release contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they are made, not misleading. No event or circumstance
has occurred or information exists with respect to the Company or its business, properties, liabilities, prospects, operations
(including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public
disclosure at or before the date hereof or announcement by the Company but which has not been so publicly disclosed. The Company
acknowledges and agrees that Buyer makes no and has not made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 2.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		4.	COVENANTS.

 

(a)               
Best Efforts. Buyer shall use its best efforts to timely satisfy each of the conditions to be satisfied by it as
provided in Section 6 of this Agreement. The Company shall use its best efforts to timely satisfy each of the conditions to be
satisfied by it as provided in Section 7 of this Agreement.

 

(b)              
Form D and Blue Sky. The Company shall file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof to Buyer promptly after filing. The Company shall, on or before the Closing Date, take such action
as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale
to the Buyer at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states
of the United States (or to obtain an exemption from such qualification), and shall provide confirmation of any such action, if
applicable, so taken to the Buyer on or prior to such Closing Date. Without limiting any other obligation of the Company under
this Agreement, the Company shall timely make all filings and reports relating to the offer and sale of the Securities required
under all applicable securities laws (including, without limitation, all applicable federal securities laws and all applicable
“Blue Sky” laws), and the Company shall comply with all applicable federal, foreign, state and local laws, statutes,
rules, regulations and the like relating to the offering and sale of the Securities to the Buyer.

 

(c)               
Reporting Status. Until the date on which the Buyer shall have sold all of the Registrable Securities (the “Reporting
Period”), the Company shall file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company
shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations
thereunder would no longer require or otherwise permit such termination.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(d)              
Use of Proceeds. The Company shall use the proceeds from the sale of the Securities for general corporate purposes.

 

(e)               
Financial Information. The Company agrees to send the following to Buyer during the Reporting Period unless the following
are filed with the SEC through EDGAR and are available to the public through the EDGAR system, (i) within one (1) Business Day
after the filing thereof with the SEC, a copy of each of its annual reports on Form 10-K, and quarterly reports on Form 10-Q, any
interim reports or any consolidated balance sheets, income statements, stockholders’ equity statements and/or cash flow statements
for any period other than annual, any current reports on Form 8-K and any registration statements (other than on Form S-8) or amendments
filed pursuant to the 1933 Act, (ii) on the same day as the release thereof, facsimile copies of all press releases issued by the
Company and (iii) copies of any notices and other information made available or given to the stockholders of the Company generally,
contemporaneously with the making available or giving thereof to the stockholders.

 

(f)               
Listing. The Company shall promptly secure the listing or designation for quotation (as the case may be) of all of
the Registrable Securities consisting of Common Stock upon each trading market and national securities exchange and automated quotation
system, if any, upon which the Common Stock is then listed or designated for quotation (as the case may be) (so that all such Registrable
Securities consisting of Common Stock may be traded on the foregoing, subject to official notice of issuance) (but in no event
later than the Closing Date) and shall maintain such listing or designation for quotation (as the case may be) of all Registrable
Securities from time to time issuable under the terms of the Transaction Documents on such national securities exchange or automated
quotation system. The Company shall maintain the Common Stock’s listing or designation for quotation (as the case may be)
on the Principal Market, The New York Stock Exchange, the NYSE Amex, the Nasdaq Global Select Market, the Nasdaq Global Market
or the Nasdaq Capital Market (each, an “Eligible Market”). The Company shall not take any action which could
be reasonably expected to result in the delisting or suspension of the Common Stock on an Eligible Market. The Company shall pay
all fees and expenses in connection with satisfying its obligations under this Section 4(f).

 

(g)              
Fees. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees,
or broker’s commissions, relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold
Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out-of-pocket
expenses) arising in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents,
each party to this Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyer.

 

(h)              
Pledge of Securities. Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges
and agrees that the Securities may be pledged by the Buyer in connection with a bona fide margin agreement or other loan or financing
arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment
of the Securities hereunder, and the Buyer effecting a pledge of Securities Buyer shall not be required to provide the Company
with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document.
At the Buyer’s expense, the Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities
may reasonably request in connection with a pledge of the Securities to such pledgee by the Buyer provided that the Company shall
be under no obligation to deliver any legal opinion required in connection therewith unless required by the Company’s transfer
agent to be issued by the Company’s legal counsel.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(i)                
Disclosure of Transactions and Other Material Information. The Company shall, on or before
8:30 a.m., New York time, on the first (1st) Business Day after the date of this Agreement, file a Current Report on Form 8-K
describing all the material terms of the transactions contemplated by the Transaction Documents in the form required by the 1934
Act and attaching all the material Transaction Documents (including, without limitation, this Agreement, the Certificate of Designation
for the Series C Preferred Shares and the form of each of the Warrants) (including all attachments, the “8-K Filing”).
From and after the date of the 8-K Filing, the Company shall have disclosed all material, non-public information (if any) delivered
to Buyer by the Company, or any of its officers, directors, employees or agents in connection with the transactions contemplated
by the Transaction Documents. The Company shall not, and the Company shall cause each of its officers, directors, employees and
agents not to, provide Buyer with any material, non-public information regarding the Company from and after the date of the 8-K
Filing without the express prior written consent of Buyer. Subject to the foregoing, neither the Company nor Buyer shall issue
any press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, the
Company shall be entitled, without the prior approval of Buyer, to make any press release or other public disclosure with respect
to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith and (ii) as is required
by applicable law and regulations (provided that in the case of clause (i) Buyer shall be consulted by the Company in connection
with any such press release or other public disclosure prior to its release). Without the prior written consent of Buyer, the
Company shall not (and shall cause each of its Affiliates to not) disclose the name of Buyer in any filing (other than the 8-K
Filing or any filing that incorporates language from the 8-K Filing and other than the Registration Statement and other than as
required by applicable law or rules and regulations), announcement, release or otherwise. Notwithstanding anything contained in
this Agreement to the contrary and without implication that the contrary would otherwise be true, the Company expressly acknowledges
and agrees that Buyer has not had, and Buyer shall not have (unless expressly agreed to by Buyer after the date hereof in a written
definitive and binding agreement executed by the Company and Buyer), any duty of confidentiality with respect to, or a duty not
to trade on the basis of, any information regarding the Company or any of its subsidiaries (as applicable) that Buyer receives
from the Company, any of its subsidiaries or any of its or its officers, directors, employees, stockholders or agents.

 

(j)                
Additional Issuance of Securities.

 

(i)                
The Company agrees that for the period commencing on the date hereof and ending on the date immediately following the 45th
day after the later of the Execution Date or satisfaction of the Registration Statement condition set forth on Annex A to the Buyer
Schedule (the “Restricted Period”), the Company shall not directly or indirectly issue, offer, sell, grant any
option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to purchase
or other disposition of) any equity security or any equity-linked or related security (including, without limitation, any “equity
security” (as that term is defined under Rule 405 promulgated under the 1933 Act), any convertible securities, debt (with
or related to equity), any preferred stock or any purchase rights).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(ii)              
Notwithstanding the foregoing restriction set forth in Section 4(j), the Company may issue: (A) shares of Common Stock or
standard options to purchase Common Stock to directors (who are also employees of the Company), officers, employees or consultants
of the Company pursuant to an Approved Share Plan (as defined below) or otherwise as approved by the board of directors prior to
the Execution Date and to directors of the Company who are not also employees of the Company, in each case, in their capacity as
such, provided that the exercise price of any such options is not lowered, none of such options are amended to increase the number
of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner
that adversely affects Buyer; (B) shares of Common Stock or Convertible Securities issued pursuant to exercise of preexisting rights
under financing agreements entered into by the Company prior to the Execution Date, including shares of Common Stock issued upon
the conversion or exercise of Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an
Approved Share Plan that are covered by clause (A) above) issued prior to the Execution Date, provided that the conversion or exercise
(as the case may be) of any such Convertible Security is made solely pursuant to the conversion or exercise (as the case may be)
provisions of such Convertible Security that were in effect on the date immediately prior to the date of this Agreement, the conversion
or exercise price of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an
Approved Share Plan that are covered by clause (A) above) is not lowered, none of such Convertible Securities are (other than standard
options to purchase Common Stock issued pursuant to an Approved Share Plan that are covered by clause (A) above) (nor is any provision
of any such Convertible Securities) amended or waived in any manner (whether by the Company or the holder thereof) to increase
the number of shares issuable thereunder and none of the terms or conditions of any such Convertible Securities (other than standard
options to purchase Common Stock issued pursuant to an Approved Share Plan that are covered by clause (A) above) are otherwise
materially changed or waived (whether by the Company or the holder thereof) in any manner that adversely affects Buyer; (C) any
registered offering in accordance with the Company’s existing Form S-3 shelf registration statement; (D) the Series C Preferred
Shares, the Conversion Shares, the Warrants, and the Warrant Shares; or (E) an issuance of Common Stock pursuant to acquisitions,
joint ventures, license arrangements, leasing arrangements and the like; the above securities in clauses (A)-(E) being the “Excluded
Securities”. “Approved Share Plan” means any employee benefit plan which has been approved by the
board of directors of the Company prior to the Execution Date pursuant to which shares of Common Stock and standard options to
purchase Common Stock may be issued to any employee, officer, director or consultant for services provided to the Company in their
capacity as such. “Convertible Securities” means any capital stock or other security of the Company that is
at any time and under any circumstances directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise
entitles the holder thereof to acquire, any capital stock or other security of the Company (including, without limitation, Common
Stock). Notwithstanding anything to the contrary in this Section 4(j), the Company may issue equity security or any equity-linked
or related security during the Restricted Period, provided that upon such issuance, the Conversion Price of the Series C Preferred
Shares and shall be adjusted to the extent provided in Section 4.2(b) of the Certificate of Designation.

 

(iii)            
The Company and each subsidiary shall be prohibited from effecting or entering into an agreement to effect any Subsequent
Placement involving a Variable Rate Transaction for a period of twelve months from the date that the Registration Statement is
declared effective. “Variable Rate Transaction” means a transaction in which the Company or any subsidiary issues
or sells any Convertible Securities at a conversion, exercise or exchange rate or other price that is based upon and/or varies
with the trading prices of, or quotations for, the shares of Common Stock at any time after the initial issuance of such Convertible
Securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial
issuance of such Convertible Securities or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock, other than pursuant to a customary “weighted average”
anti-dilution provision or (ii) enters into any agreement (including, without limitation, an “equity line of credit”
or an “at the market offering”) whereby the Company or any subsidiary may sell securities at a future determined price
(other than standard and customary “preemptive” or “participation” rights). Buyer shall be entitled to
obtain injunctive relief against the Company and its subsidiaries (as applicable) to preclude any such issuance, which remedy shall
be in addition to any right to collect damages.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(iv)            
As long as the Buyer’s Series C Preferred Shares with a stated value of at least $250,000 remain outstanding, the
Company shall not, without the consent of the holders of a majority of the outstanding Series C Preferred Shares, issue debt securities
or any shares of preferred stock that are senior to or pari passu with the Buyer’s Series C Preferred Shares, except
for issuances pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar transactions.

 

(k)              
Reservation of Shares. As long as any of the Series C Preferred Shares or Warrants remain outstanding, the Company
shall take all action necessary to at all times have authorized and from time to time to have authorized, and reserved for the
purpose of issuance, no less than 150% of the number of shares of Common Stock issuable upon conversion of the Series C Preferred
Shares and exercise of the Warrants (assuming the Series C Preferred Shares and Warrants are converted and exercisable in full
and without regard to any limitations on the exercise of the Warrants set forth therein).

 

(l)                
Conduct of Business. The business of the Company shall not be conducted in violation of any law, ordinance or regulation
of any governmental entity, except where such violations would not result, either individually or in the aggregate, in a Material
Adverse Effect.

 

(m)            
Passive Foreign Investment Company. The Company shall conduct its business in such a manner as will ensure that the
Company will not be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the U.S. Internal
Revenue Code of 1986, as amended.

 

(n)              
Corporate Existence. So long as Buyer owns any Series C Preferred Shares or Warrants, the Company shall not be party
to any Fundamental Transaction (as defined in the Warrants) unless the Company is in compliance with the applicable provisions
governing Fundamental Transactions set forth in the Series C Preferred Shares and the Warrants.

 

(o)              
Activity Restrictions. For so long as the Buyer or any of its Affiliates holds any Securities, neither the Buyer
nor any Affiliate will: (i) vote any shares of Common Stock owned or controlled by it, solicit any proxies, or seek to advise or
influence any Person with respect to any voting securities of the Company; (ii) engage or participate in any actions, plans or
proposals which relate to or would result in (A) acquiring additional securities of the Company, alone or together with any other
Person, which would result in beneficially owning or controlling, or being deemed to beneficially own or control, more than 9.9%
of the total outstanding Common Stock or other voting securities of the Company, (B) an extraordinary corporate transaction, such
as a merger, reorganization or liquidation, involving Company, (C) a sale or transfer of a material amount of assets of the Company,
(D) any change in the present board of directors or management of the Company, including any plans or proposals to change the number
or term of directors or to fill any existing vacancies on the board, (E) any material change in the present capitalization or dividend
policy of the Company, (F) any other material change in the Company’s business or corporate structure, (G) changes in the
Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control
of the Company by any Person, (H) causing a class of securities of the Company to be delisted from a national securities exchange
or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association,
(I) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4)
of the Act, or (J) any action, intention, plan or arrangement similar to any of those enumerated above; or (iii) request the Company
or its directors, officers, employees, agents or representatives to amend or waive any provision of this Section.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		5.	REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

(a)               
Register. The Company shall maintain at its principal executive offices (or such other office or agency of the Company
as it may designate by notice to each holder of Securities), a register for the Series C Preferred Shares and the Warrants in which
the Company shall record the name and address of the Person in whose name the Series C Preferred Shares and the Warrants have been
issued (including the name and address of each transferee) reflecting the Series C Preferred Shares held by such Person and the
Warrants held by such Person. The Company shall keep the register open and available at all times during business hours for inspection
by Buyer or its legal representatives.

 

(b)              
Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent and any subsequent
transfer agent in a form acceptable to the Buyer to issue certificates or credit shares to the applicable balance accounts at The
Depository Trust Company (“DTC”), registered in the name of Buyer or its respective nominee(s), for the Conversion
Shares and the Warrant Shares in such amounts as specified from time to time by Buyer to the Company, and confirmed by the Company,
upon conversion of the Series C Preferred Shares or the exercise of the Warrants (as the case may be). The Company represents and
warrants that no instruction other than such irrevocable transfer agent instructions referred to in this Section 5(b), and stop
transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its transfer agent with respect to
the Securities, and that the Securities shall otherwise be freely transferable on the books and records of the Company, as applicable,
to the extent provided in this Agreement and the other Transaction Documents. If Buyer effects a sale, assignment or transfer of
the Securities in accordance with Section 2(g), the Company shall permit the transfer and shall promptly instruct its transfer
agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations
as specified by Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves
Conversion Shares or Warrant Shares sold, assigned or transferred pursuant to an effective registration statement or in compliance
with Rule 144 or another exemption from registration, the transfer agent shall issue such shares to Buyer, assignee or transferee
(as the case may be) without any restrictive legend in accordance with Section 5(d) below. The Company acknowledges that a breach
by it of its obligations hereunder will cause irreparable harm to Buyer. Accordingly, the Company acknowledges that the remedy
at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Section 5(b), that Buyer shall be entitled, in addition to all other available
remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity
of showing economic loss and without any bond or other security being required. The Company shall cause its counsel to issue the
legal opinion referred to in the irrevocable transfer agent instructions to the Company’s transfer agent on the Effective
Date (as defined in the Registration Rights Agreement). Any fees (with respect to the transfer agent, counsel to the Company or
otherwise) associated with the issuance of such opinion or the removal of any legends on any of the Securities shall be borne by
the Company.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(c)               
Legends. Buyer understands that the Securities have been issued (or will be issued in the case of the Conversion
Shares and the Warrant Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state
securities laws, and except as set forth below, the Securities shall bear any legend as required by the “Blue Sky”
laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against
transfer of such stock certificates):

 

[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE] [EXERCISABLE] HAVE BEEN][THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT
FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE
COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

(d)              
Removal of Legends. Certificates evidencing Securities shall not be required to contain the legend set forth in Section
5(c) above or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such
Securities is effective under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the transferor
is not an Affiliates of the Company), (iii) if such Securities are eligible to be sold, assigned or transferred under Rule 144
(provided that Buyer provides the Company with reasonable assurances that such Securities are eligible for sale, assignment or
transfer under Rule 144 which shall not include an opinion of counsel), (iv) in connection with a sale, assignment or other transfer
(other than under Rule 144), provided that Buyer provides the Company with an opinion of counsel to Buyer from reputable counsel
to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements
of the 1933 Act or (v) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation,
controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing,
the Company shall no later than five (5) Trading Days following the delivery by Buyer to the Company or the transfer agent (with
notice to the Company) of a legended certificate representing such Securities (endorsed or with stock powers attached, signatures
guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with any other deliveries
from Buyer as may be required above in this Section 5(d), as directed by Buyer, either: (A) provided that the Company’s transfer
agent is participating in the DTC Fast Automated Securities Transfer Program and such Securities are Conversion Shares or Warrant
Shares, credit the aggregate number of shares of Common Stock to which Buyer shall be entitled to Buyer’s or its designee’s
balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Company’s transfer agent is not
participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable overnight courier) to Buyer,
a certificate representing such Securities that is free from all restrictive and other legends, registered in the name of Buyer
or its designee (the date by which such credit is so required to be made to the balance account of Buyer’s or Buyer’s
nominee with DTC or such certificate is required to be delivered to Buyer pursuant to the foregoing is referred to herein as the
“Required Delivery Date”).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		(e)	Failure to Timely Deliver; Buy-In. If the Company fails to issue and deliver (or cause to
be delivered) to Buyer by the Required Delivery Date a certificate representing the Securities so delivered to the Company by Buyer
that is free from all restrictive and other legends or credit the balance account of Buyer’s or Buyer’s nominee with
DTC for such number of Securities so delivered to the Company, then, in addition to all other remedies available to Buyer, at the
sole discretion of Buyer, the Company shall:

 

(i)pay in cash to Buyer on each Trading
Day after the Required Delivery Date that the issuance or credit of such shares is not timely effected an amount equal to 2% of
the product of (A) the number of shares of Common Stock not so delivered or credited (as the case may be) to Buyer or Buyer’s
nominee multiplied by (B) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the Required Delivery
Date; or

 

(ii)if on or after the Required Delivery
Date, Buyer (or any other Person in respect, or on behalf, of Buyer) purchases (in an open market transaction or otherwise) shares
of Common Stock to deliver in satisfaction of a sale by Buyer of all or any portion of the number of shares of Common Stock, or
a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock, that Buyer so
anticipated receiving from the Company without any restrictive legend, then, within five (5) Trading Days after Buyer’s request
and in Buyer’s sole discretion, either (A) pay cash to Buyer in an amount equal to Buyer’s total purchase price (including
brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to so deliver such certificate or credit Buyer’s balance
account shall terminate and such shares shall be cancelled, or (B) promptly honor its obligation to so deliver to Buyer a certificate
or certificates or credit Buyer’s DTC account representing such number of shares of Common Stock that would have been so
delivered if the Company timely complied with its obligations hereunder and pay cash to Buyer in an amount equal to the excess
(if any) of the Buy-In Price over the product of (1) such number of shares of Common Stock that the Company was required to deliver
to Buyer by the Required Delivery Date multiplied by (2) the lowest Closing Sale Price (as defined in the Warrants) of the Common
Stock on any Trading Day during the period commencing on the date of the delivery by Buyer to the Company of the applicable Conversion
Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (B).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		6.	CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

(a)               
The obligation of the Company hereunder to issue and sell the Series C Preferred Shares and the related Warrants to Buyer
at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that
these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by
providing Buyer with prior written notice thereof:

 

(i)                
Buyer shall have executed each of the other Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii)              
Buyer and each other Buyer shall have delivered to the Company the Purchase Price for the Common Stock, Series C Preferred
Shares and Warrants being purchased by Buyer at the Closing by wire transfer of immediately available funds pursuant to the wire
instructions provided by the Company.

 

(iii)            
The representations and warranties of Buyer set forth in Section 2 shall be true and correct in all material respects as
of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties
that speak as of a specific date, which shall be true and correct as of such date), and Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied
or complied with by Buyer at or prior to the Closing Date.

 

(iv)            
Buyer shall have executed and delivered, to the reasonable satisfaction of the Company, such questionnaires and documents
in support thereof that the Company and its agents deem reasonably necessary (or prudent) to comply with the requirements of Regulation
D with respect to the transactions contemplated by this Agreement.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

		7.	CONDITIONS TO BUYER’S OBLIGATION TO PURCHASE.

 

(a)               
The obligation of Buyer hereunder to purchase its Series C Preferred Shares and related Warrants at the Closing is subject
to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for
Buyer’s sole benefit and may be waived by Buyer at any time in its sole discretion by providing the Company with prior written
notice thereof:

 

(i)                
The Company shall have duly executed and delivered to Buyer each of the Transaction Documents to which it is a party and
the Company shall have duly executed and delivered to Buyer the Warrants and Series C Preferred Shares as is set forth on the Buyer
Schedule and the Company shall have complied in all respects with all obligations under this Agreement and the other Transaction
Documents, including, without limitation, the Certificate of Designation and the Warrants. Notwithstanding the foregoing, the Company
shall be entitled to deliver to Buyer evidence of the issuance of the Preferred Shares by book entry within five (5) Business Days
after the Closing.

 

(ii)              
The Company shall have delivered to Buyer a certificate, in the form previously provided to the Company by Buyer, executed
by the Secretary of the Company and dated as of the Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted
by the Company’s board of directors in a form reasonably acceptable to Buyer, (ii) the Certificate of Incorporation of the
and (iii) the Bylaws of the Company as in effect at the Closing.

 

(iii)            
Each and every representation and warranty of the Company shall be true and correct in all material respects as of the date
when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak
as of a specific date, which shall be true and correct in all material respects as of such date) and the Company shall have performed,
satisfied and complied in all material respects with the covenants, agreements and conditions required to be performed, satisfied
or complied with by the Company at or prior to the Closing Date, including, without limitation the issuance of all Securities prior
to the Closing Date as required by the Transaction Documents and the Company has a sufficient number of duly authorized shares
of Common Stock reserved for issuance as may be required to fulfill its obligations pursuant to the Transaction Documents. Buyer
shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the
foregoing effect and as to such other matters as may be reasonably requested by Buyer in the form reasonably acceptable to Buyer.

 

(iv)            
The Company shall have delivered to Buyer information from the Company’s transfer agent certifying the number of shares
of Common Stock outstanding on the Closing Date immediately prior to the Closing.

 

(v)              
The Common Stock (I) shall be designated for quotation on the Principal Market and (II) shall not have been suspended, as
of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or
the Principal Market have been threatened, as of the Closing Date, either (A) in writing by the SEC or the Principal Market or
(B) by falling below the minimum maintenance requirements of the Principal Market; since January 1, 2016, the Company shall have
timely complied (taking into account any valid extensions for which the Company has qualified) with all filing and reporting obligations
under the federal securities laws; the Company is in compliance with all requirements in order to maintain quotation on the Principal
Market (including reporting requirements under the 1934 Act).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(vi)            
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for
the sale of the Securities, including without limitation, those required by the Principal Market.

 

(vii)            No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents, and no actions, suits or proceedings shall be in progress or pending by any Person that
seeks to enjoin, prohibit or otherwise adversely affect any of the transactions contemplated by the Transaction Documents.

 

(viii)           Except as set forth in Schedule 7(a)(viii), no event of default exists or has occurred for which the Company has received
a notice from a lender, under any outstanding loan or credit facility to which the Company or any of its subsidiaries is a party,
in connection with a breach of a financial covenant set forth in the governing agreement of such loan or credit facility;

 

(ix)            
The Company shall have delivered to Buyer such other documents, instruments or certificates relating to the transactions
contemplated by this Agreement reasonably required to consummate the transactions contemplated hereby.

 

(x)              
Such other conditions which are set forth on Annex A to the Buyer Schedule.

 

8.                 
RIGHT OF PARTICIPATION. The Parties acknowledge and agree that the Buyer shall have the right, but not
the obligation, to participate in up to one-third of the aggregate offering amount of the offer of shares of series D preferred
stock of the Company or similar financing round of the Company.

 

9.                  MISCELLANEOUS.

 

(a)               
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of New York, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for
the adjudication of any dispute hereunder or under any of the other Transaction Documents or in connection herewith or therewith
or with any transaction contemplated hereby or thereby or discussed herein or therein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed
or operate to preclude Buyer from bringing suit or taking other legal action against the Company in any other jurisdiction to collect
on the Company’s obligations to Buyer or to enforce a judgment or other court ruling in favor of Buyer. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(b)              
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document
format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original
thereof.

 

(c)               
Headings; Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or
affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed
to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,”
“include” and words of like import shall be construed broadly as if followed by the words “without limitation.”
The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement
instead of just the provision in which they are found.

 

(d)              
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(e)               
Entire Agreement; Amendments. This Agreement, the other Transaction Documents and the schedules and exhibits attached
hereto and thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between
the Buyer, the Company, its Affiliates and Persons acting on its behalf solely with respect to the matters contained herein and
therein, and this Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments
referenced herein and therein contain the entire understanding of the parties solely with respect to the matters covered herein
and therein. Except as specifically set forth herein or therein, neither the Company nor Buyer makes any representation, warranty,
covenant or undertaking with respect to such matters. For clarification purposes, the Recitals are part of this Agreement. No provision
of this Agreement may be amended other than by an instrument in writing signed by the Company and Buyer. No waiver shall be effective
unless it is in writing and signed by an authorized representative of the waiving party. No consideration shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same
consideration also is offered to all of the parties to the Transaction Documents, all holders of Series C Preferred Shares or all
holders of the Warrants (as the case may be). The Company has not, directly or indirectly, made any agreements with Buyer relating
to the terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction
Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, Buyer has not made
any commitment or promise or has any other obligation to provide any financing to the Company or otherwise. As a material inducement
for Buyer to enter into this Agreement, the Company expressly acknowledges and agrees that (i) no due diligence or other investigation
or inquiry conducted by Buyer, any of its advisors or any of its representatives shall affect Buyer’s right to rely on, or
shall modify or qualify in any manner or be an exception to any of, the Company’s representations and warranties contained
in this Agreement or any other Transaction Document and (ii) unless a provision of this Agreement or any other Transaction Document
is expressly preceded by the phrase “except as disclosed in the SEC Documents,” nothing contained in any of the SEC
Documents shall affect Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the
Company’s representations and warranties contained in this Agreement or any other Transaction Document.

 

(f)               
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, if delivered personally; (ii)
when sent, if sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on
file by the sending party); (iii) when sent, if sent by e-mail (provided that such sent e-mail is kept on file (whether electronically
or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient’s
e-mail server that such e-mail could not be delivered to such recipient) and (iv) if sent by overnight courier service, one (1)
Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed
to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

If to the Company:

 

Skyline Medical Inc.

2915 Commers Drive

Suite 900

Eagan, MN 55121

Telephone: (651) 389-4800

Facsimile:

Attention: Bob Myers, CFO

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

With a copy (for informational purposes only) to:

 

Maslon LLP

3300 Wells Fargo Center

90 South Seventh Street

Minneapolis, MN 55402

Telephone: (612) 672-8200

Facsimile: (612) 672-8397

Email: martin.rosenbaum@maslon.com

Attention: Martin R. Rosenbaum, Esq.

 

If to the Transfer Agent:

 

Corporate Stock Transfer, Inc.

3200 Cherry Creek South Drive

Suite 430

Denver, CO 80209

Telephone: (303) 282-4800

Facsimile:

Email: knaughton@corporatestock.com

Attention: Karen Naughton

 

If to Buyer:

 

Esousa Holdings LLC

211 East 43rd Street

Suite 402

New York, NY 10017

Telephone: (646) 278-6785

Facsimile: (212) 732-1131

Email: Amy@credecg.com

Attention: Amy Talizabadeh

 

with a copy (for informational purposes only) to:

 

McDermott Will & Emery LLP

340 Madison Ave.

New York, NY 10173

Telephone: (212) 547-5585

Facsimile: (212) 547-5444

E-mail: Rcohen@mwe.com

Attention: Robert Cohen, Esq.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

or to such other address, facsimile number or e-mail address and/or
to the attention of such other Person as the recipient party has specified by written notice given to each other party five (5)
days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing
the time, date and recipient facsimile number or (C) provided by an overnight courier service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iv) above, respectively.
A copy of the e-mail transmission containing the time, date and recipient e-mail address shall be rebuttable evidence of receipt
by e-mail in accordance with clause (iii) above.

 

(g)              
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and its successors
and assigns, including, as contemplated below, any assignee of any of the Securities. The Company shall not assign this Agreement
or any rights or obligations hereunder without the prior written consent of the Buyer, including, without limitation, by way of
a Fundamental Transaction (as defined in the Certificate of Designation or the Warrants) (unless the Company is in compliance with
the applicable provisions governing Fundamental Transactions set forth in the applicable Certificate of Designation or Warrant).

 

(h)              
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and its permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than
the Indemnitees referred to in Section 9(k).

 

(i)                
Survival. The representations, warranties, agreements and covenants shall survive the Closing. Buyer shall be responsible
only for its representations, warranties, agreements and covenants hereunder.

 

(j)                
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(k)              
Indemnification(i). In consideration of Buyer’s execution and delivery of the Transaction Documents and acquiring
the Securities thereunder and in addition to all of the Company’s other obligations under the Transaction Documents, the
Company shall defend, protect, indemnify and hold harmless Buyer and each holder of any Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents
or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this
Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and reasonable and documented expenses in connection therewith
(irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including
reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee
as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by
the Company in any of the Transaction Documents, (b) any breach of any covenant, agreement or obligation of the Company contained
in any of the Transaction Documents or (c) any cause of action, suit, proceeding or claim brought or made against such Indemnitee
by a third party (including for these purposes a derivative action brought on behalf of the Company) or which otherwise involves
such Indemnitee that arises out of or results from (i) the execution, delivery, performance or enforcement of any of the Transaction
Documents, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the
issuance of the Securities, (iii) any disclosure properly made by Buyer pursuant to Section 4(i), or (iv) the status of Buyer or
holder of the Securities either as an investor in the Company pursuant to the transactions contemplated by the Transaction Documents
or as a party to this Agreement (including, without limitation, as a party in interest or otherwise in any action or proceeding
for injunctive or other equitable relief), unless such action is based primarily upon a breach of Buyer’s representations,
warranties, or covenants under the Transaction Documents or any violations by Buyer of state or federal securities laws or any
conduct by Buyer which constitutes fraud, gross negligence or willful misconduct. To the extent that the foregoing undertaking
by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable law.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(i)                
Promptly after receipt by an Indemnitee under this Section 9(k) of notice of the commencement of any action or proceeding
(including any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in respect
thereof is to be made against the Company under this Section 9(k), deliver to the Company a written notice of the commencement
thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of
the defense thereof with counsel mutually satisfactory to the Company and the Indemnitee; provided, however, that an Indemnitee
shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the Company if: (i) the
Company has agreed in writing to pay such fees and expenses; (ii) the Company shall have failed promptly to assume the defense
of such Indemnified Liability and to employ counsel reasonably satisfactory to such Indemnitee in any such Indemnified Liability;
or (iii) the named parties to any such Indemnified Liability (including any impleaded parties) include both such Indemnitee and
the Company, and such Indemnitee shall have been advised by counsel that a conflict of interest is likely to exist if the same
counsel were to represent such Indemnitee and the Company (in which case, if such Indemnitee notifies the Company in writing that
it elects to employ separate counsel at the expense of the Company, then the Company shall not have the right to assume the defense
thereof and such counsel shall be at the expense of the Company), provided further, that in the case of clause (iii) above the
Company shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for such Indemnitee.
The Indemnitee shall reasonably cooperate with the Company in connection with any negotiation or defense of any such action or
Indemnified Liability by the Company and shall furnish to the Company all information reasonably available to the Indemnitee which
relates to such action or Indemnified Liability. The Company shall keep the Indemnitee reasonably apprised at all times as to the
status of the defense or any settlement negotiations with respect thereto. The Company shall not be liable for any settlement of
any action, claim or proceeding effected without its prior written consent, provided, however, that the Company shall not unreasonably
withhold, delay or condition its consent. The Company shall not, without the prior written consent of the Indemnitee, consent to
entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof
the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liability
or litigation, and such settlement shall not include any admission as to fault on the part of the Indemnitee. Following indemnification
as provided for hereunder, the Company shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the Company
within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnitee
under this Section 9(k), except to the extent that the Company is materially and adversely prejudiced in its ability to defend
such action.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(ii)              
The indemnification required by this Section 9(k) shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or Indemnified Liabilities are incurred.

 

(iii)            
Notwithstanding any provision in this Agreement or any other Transaction Documents, the aggregate indemnification obligations
of the Company pursuant to this Section 9(k) shall not exceed 100% of the aggregate Purchase Price actually paid by Buyer.

 

(iv)            
The sole and exclusive remedies for any breach of any representation, warranty, covenant or agreement hereunder shall be
the indemnification provided by this Section 9(k), and Buyer expressly waives any other rights or remedies it may have; provided
however, that equitable relief, including remedies of specific performance and injunction, shall be available with respect to any
matter where money damages would not be sufficient to compensate Buyer or to preserve the rights of Buyer pending resolution of
a dispute, and this Section 9(k) shall not relieve the Company from liability for willful misconduct, gross negligence, bad faith,
fraud or willful breach of any of its representations, warranties, covenants or agreements set forth in this Agreement.

 

(l)                
Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. No specific representation or warranty
shall limit the generality or applicability of a more general representation or warranty. Each and every reference to share prices,
shares of Common Stock and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted
for stock dividends, stock splits, stock combinations and other similar transactions that occur with respect to the Common Stock
after the date of this Agreement.

 

(m)            
Remedies. Buyer and each holder of any Securities shall have all rights and remedies set forth in the Transaction
Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and
all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall
be entitled to enforce such rights specifically (without posting a bond or other security, to the extent permitted by law), to
recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore,
the Company recognizes that in the event that it fails to perform, observe, or discharge any or all of its obligations under the
Transaction Documents, any remedy at law may prove to be inadequate relief to the Buyer. The Company therefore agrees that the
Buyer shall be entitled to seek specific performance and/or temporary, preliminary and permanent injunctive or other equitable
relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting
a bond or other security.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

(n)              
Exercise of Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) the Transaction Documents, whenever Buyer exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then Buyer may continue to exercise
it other rights, elections, demands and options hereunder and under any other Transaction Document from time to time as if such
original right, election, demand or option had not been exercised without prejudice to its future actions and rights and remedies.

 

(o)              
Payment Set Aside; Currency(p). To the extent that the Company makes a payment or payments to Buyer hereunder or
pursuant to any of the other Transaction Documents or Buyer enforces or exercises its rights hereunder or thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared
to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise
restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy
law, foreign, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment
had not been made or such enforcement or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred
to in this Agreement and the other Transaction Documents are in United States Dollars (“U.S. Dollars”), and
all amounts owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated
in other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on
the date of calculation. “Exchange Rate” means, in relation to any amount of currency to be converted into
U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant
date of calculation.

 

[Signature Pages Follow]

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

IN WITNESS WHEREOF, each of Buyer and the
Company has caused its signature page to this Agreement to be duly executed as of the date first written above.

 

		COMPANY

	 	 
	 	SKYLINE MEDICAL INC.
	 	 
	
         

        

        

        
	By:	/s/ Bob Myers
	 	 	Name: Bob Myers
	 	 	Title: Chief Financial Officer

 

 

 

 

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

 

IN WITNESS WHEREOF, each of Buyer and
the Company has caused its signature page to this Agreement to be duly executed as of the date first written above.

 

		BUYER:

	 	 
	 	ESOUSA HOLDINGS LLC
	 	 
	
         

        

        

        
	By:	/s/ Rachel Glicksman
	 	 	Name: Rachel Glicksman
	 	 	Title: Managing Member

 

 

 

 

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

BUYER SCHEDULE

 

Name of Buyer: Esousa Holdings LLC

 

The Series C Preferred Shares to be purchased
and sold at Closing: Number of Series C Preferred Shares of an aggregated stated value of $1,300,000, convertible at a 15%
discount to the lower of the (i) the closing bid price per share of the Company’s Common Stock on the day immediately prior
to the Execution Date or (ii) the closing bid price per share of the Company’s Common Stock on the day immediately prior
to the effective date of the Registration Statement (as defined in the Registration Rights Agreement) (the day on which the lower
price of (i) or (ii) occurs is the “Measurement Date”) (the “Conversion Price”). The Company
shall declare and pay dividends of 6% on the stated value of each Series C Preferred Share on the date that is six months after
the Execution Date and on each date that is six months after the previous such dividend payment date, or if such date is not a
Business Day, then the first date thereafter that is a Business Day (each a “Dividend Payment Date”); provided,
however, that if the closing bid price of the Company’s Common Stock on the first Dividend Payment Date (the “First
Dividend Price”) is lower than the closing bid price of the Company’s Common Stock on the day immediately prior
to the Execution Date (the “Closing Price”), the dividend percentage per Series C Preferred Share payable on
the first Dividend Payment Date shall be equal to six percent (6%) of the stated value per share plus a percentage of the stated
value per share equal to (a) one-half of the number of Series C Preferred Shares issued to the Buyer on the Execution Date multiplied
by the Closing Price, multiplied by (b) the quotient of (1) the difference between (x) the Closing Price and (y) the First Dividend
Price, divided by (2) the Closing Price, divided by (c) $1,300,000. The Series C Preferred Shares shall begin to amortize through
mandatory redemption, if not previously converted, at the option of the Investor starting on the twelve-month anniversary of the
Execution Date, such that the Series C Preferred Shares will be fully redeemed by mandatory redemption by the 24-month anniversary
of the date of issuance, unless prohibited by Delaware law governing distributions to shareholders.

 

Illustrative First Dividend Payment Calculation

 

For example, if there are 1,213,819 outstanding
Series C Preferred Shares issued on the Execution Date, the Closing Price is $1.26 per each share of Common Stock and the First
Dividend Price is $1.000 per each share of Common Stock (20.6% lower than the Closing Price), then the dividend percentage of the
$1.071* stated value for the dividend payable on the first Dividend Payment Date will be 16.63%, as follows:

 

 

((1,213,819 / 2) X 1.26) X (($1.26 - $1.00)
/ 1.26) / $1,300,000) + 0.06 = 0.18138

 

18.138% of the stated value of $1.071 = $0.19426
per preferred share, or $235,796 paid on 1,213,819 shares

 

Warrants to be issued to Buyer at Closing:
for no additional consideration, 5.5 year warrants to acquire one share of Common Stock for every two shares of Common Stock that
the Series C Preferred Shares are convertible into.

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

 

Six months after the Execution Date, the Warrants
may be exercised at the price equal to the market value of the Company’s Common Stock on the Execution Date (“Exercise
Price”). In no event will the Exercise Price be less than the market value of the Common Stock on the Execution Date.

 

*Note: the “stated value” under the Certificate
of Designation is $1.3M divided by 1,213,819, or $1.071 – based on the 15% discount to the $1.26 closing bid price used to
calculate the initial amounts.

 

 

    
DM_US 86580026-11.096039.0012
4824-4668-8343, v. 1

     

    

 

ANNEX A TO BUYER SCHEDULE

 

Effectiveness of Registration Statement Condition

 

Buyer’s release from the restrictive covenant
set forth in Section 4(j) of this Agreement is subject to the fulfillment of the following condition:

 

		1.	The Registration Statement, which must be filed within 15 days of the Execution Date, (as defined
in the Registration Rights Agreement) on Form S-3 has been declared effective by the SEC and covers the sale by Buyer (in accordance
with the plan of distribution called for by the Registration Rights Agreement) of the Common Stock contemplated by, and in the
amount of, the Required Registration Amount (as defined in the Registration Rights Agreement) and there has been no Equity Conditions
Failure (as defined in the Warrants). If the Registration Statement is not declared effective within 45 days of the Execution Date,
the Company shall incur penalties of 1.5% per month for each month, or partial month, that the SEC fails to declare such Initial
Registration Statement Effective. Such penalties shall lapse upon the six-month anniversary of the Execution Date so long as the
Buyer’s Common Stock are eligible for sale, without restriction, under Rule 144.

 

 

 

 

 

 

 

DM_US
86580026-11.096039.0012

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]